Small cell lung cancer, especially in its limited stage, poses significant treatment challenges due to its aggressive nature and rapid progression. The standard-of-care protocol involves chemoradiation therapy employing thoracic radiotherapy combined with platinum-based chemotherapy. The NRG-LU005 trial was designed to evaluate whether adding atezolizumab concurrently and as an adjuvant therapy may improve not only survival outcomes but also the quality of life (QOL) for patients enduring this demanding regimen. The trial randomized 544 patients to receive either chemoradiation alone or with concurrent and adjuvant atezolizumab. Radiation therapy schedules included twice-daily radiotherapy at 45 Gy or once-daily at 66 Gy, though the randomization did not encompass radiation schedule assignment.

The primary endpoint of the trial, overall survival, did not show a statistically significant benefit from the addition of atezolizumab. However, an intriguing exploratory analysis pointed to a notable survival advantage in patients who underwent twice-daily radiation compared to once-daily radiation schedules, despite the lack of randomization between these two modalities. Building on these findings, the recent PRO analysis focused on assessing the longitudinal quality of life in these patients using validated instruments such as the Functional Assessment of Cancer Therapy – Trial Outcome Index (FACT-TOI), EQ-5D-5L, and PROMIS-Fatigue.

Compliance with PRO assessments remained impressively high, exceeding 85% at baseline and stabilizing to approximately 60-68% across a 21-month follow-up period post-chemoradiation. This level of engagement, especially in a population experiencing intensive treatment and disease burden, underscores the relevance and reliability of these patient-centered data. As anticipated, patients reported a decline in FACT-TOI scores during active chemoradiation, indicative of the acute toxicities and symptomatic burden associated with simultaneous chemotherapy and radiation. Encouragingly, recovery trajectories showed improvement by the three-month post-treatment mark, with stabilization or even surpassing of baseline QOL scores observed from six months onward.

Strikingly, fewer patients in the atezolizumab arm experienced clinically meaningful decline (CMD) in quality of life at 21 months compared to those receiving chemoradiation alone (25% versus 38%). This finding points toward a potential additive benefit of immunotherapy in ameliorating longer-term treatment-related decrements in patient wellness, which may not be directly reflected in survival statistics alone. Furthermore, the twice-daily radiation cohort demonstrated relatively superior QOL outcomes over time compared to the once-daily radiation group. Multivariable analyses adjusting for confounders corroborated these observations, lending credence to the hypothesis that twice-daily treatment schedules might confer qualitative advantages without compromising efficacy.

Dr. Benjamin Movsas, the principal quality of life investigator for the NRG-LU005 study and Medical Director at Henry Ford Cancer in Michigan, highlighted the significance of these results from a patient-centered perspective. He emphasized that although the trial was not designed to randomize radiation fractionation schedules, the association of twice-daily radiation with enhanced QOL metrics underscores the importance of considering patient-reported outcomes in treatment design. These data reinforce the acceptability and potential preference for accelerated radiation regimens in LS-SCLC, which historically have been underutilized in clinical practice despite prior indications of improved survival.

The NRG-LU005 trial leveraged a comprehensive and methodologically rigorous approach to capturing patient-reported outcomes, ensuring that the nuanced impacts of therapy beyond traditional clinical endpoints are recognized. The integration of FACT-TOI, EQ-5D-5L, and PROMIS-Fatigue instruments provided a multidimensional evaluation encompassing physical, emotional, and functional domains, reflecting the holistic experience of LS-SCLC patients undergoing intensive multimodal therapy. This approach aligns with emerging oncology paradigms prioritizing not only prolongation of life but also preservation and enhancement of its quality.

Of particular technical interest, the study’s analysis delineated the temporal patterns of QOL changes, substantiating the transient nature of acute treatment toxicities during chemoradiation followed by encouraging recovery phases. The identification of a lower frequency of clinically meaningful QOL deterioration in the immunotherapy arm suggests immunomodulatory treatments might mitigate some long-term sequelae of concurrent chemoradiation. Mechanistically, this could relate to modulation of systemic inflammatory responses or immune-related effects on tumor and normal tissue homeostasis, warranting further translational investigation.

The trial’s funding was supported by the National Cancer Institute and Genentech, facilitating the execution of this large-scale, multi-institutional study. NRG Oncology’s broad network of over 1,300 research sites worldwide was instrumental in achieving high accrual rates and maintaining robust data quality, exemplifying the power of collaborative clinical research in oncology. This infrastructure allows for definitive evaluation of complex treatment interventions and their impact on diverse patient populations, advancing the standard of care.

Importantly, these findings may influence future clinical guidelines and patient counseling practices in LS-SCLC. The demonstration of quality of life benefits with twice-daily radiation and concurrent immunotherapy provides a compelling rationale for incorporating patient-centered endpoints in clinical trial design and treatment decision-making. It also urges consideration of twice-daily radiation schedules, often avoided due to logistical challenges, as a viable option that may offer tangible advantages from the perspective of those receiving therapy.

In conclusion, while overall survival gains remain elusive in this setting, the NRG-LU005 patient-reported outcomes analysis marks a pivotal step in understanding how therapeutic regimens influence quality of life over the long term for limited-stage small cell lung cancer patients. These nuanced insights enhance the precision of clinical practice, balancing efficacy with patient experience. Ongoing research is necessary to optimize integrated treatment strategies further and to elucidate the biological underpinnings of observed QOL differences, ultimately striving to improve both quantity and quality of survival.

Subject of Research: Limited-stage small cell lung cancer treatment; integration of immunotherapy with chemoradiation; patient-reported outcomes and quality of life analysis.

Article Title: Comprehensive Patient-Reported Outcomes from NRG-LU005: Evaluating Chemoradiation with and without Atezolizumab in Limited-Stage Small Cell Lung Cancer

News Publication Date: September-October 2025

Web References:
– NRG Oncology Podcast: https://www.nrgoncology.org/Podcast
– NRG Oncology Homepage: http://www.nrgoncology.org

References:
Movsas B, Hu C, Higgins KA, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Xiao C, Shoji T, Faller BA, Mohindra P, Dib EG, Brownstein JM, Chun SG, Kuzma CS, Kotecha RR, Onitilo AA, Paulus R, Bradley JD, Bruner DW. Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC). Paper presented during the Late Breaking Abstract Session at the annual meeting of the American Society for Radiation Oncology. San Francisco, CA. (2025, September-October).

Keywords: Small cell lung cancer, limited-stage, chemoradiation, atezolizumab, immunotherapy, patient-reported outcomes, quality of life, thoracic radiotherapy, twice-daily radiation, concurrent therapy, clinical trial, NRG Oncology

Dr. Bredel’s keynote presentation, entitled “Precision Without Incision: The New Era of Functional Radiosurgery,” emphasized the transformative potential of integrating advanced imaging modalities with radiosurgical techniques. By employing high-resolution connectomics—the comprehensive mapping of neural connections—clinicians can now tailor radiation treatments with unprecedented accuracy. This approach minimizes collateral damage to healthy brain tissue while maximizing the destruction of targeted pathological areas, thereby enhancing both efficacy and safety.

The core of this methodology lies in the convergence of several cutting-edge technologies. High-definition magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), and functional MRI (fMRI) provide multidimensional maps of the brain’s functional and structural networks. When combined with stereotactic radiosurgery platforms, such as Gamma Knife and CyberKnife, these imaging technologies facilitate the delivery of concentrated high-dose radiation to precise locations within complex neural circuits implicated in movement disorders like Parkinson’s disease, essential tremor, and dystonia.

The implications of such precision treatment are profound. Traditional surgical neuronal interventions often entail significant risks, including infection, hemorrhage, and lengthy recovery periods. Image-guided radiosurgery circumvents these challenges by offering a nonsurgical alternative that is both minimally invasive and outpatient-based. Patients can expect reduced procedure times, fewer complications, and faster return to daily activities—all while benefiting from highly effective neuromodulation and lesioning.

Expanding the horizon, Sylvester Comprehensive Cancer Center’s researchers are concurrently advancing complementary themes in radiation oncology that underscore personalized medicine’s growing prominence. Among these is Dr. Amanda Rivera’s exploration of disparities in gynecologic cancer treatment access and care quality, highlighting the pressing need for customized therapeutic frameworks. Similarly, Dr. Alan Dal Pra’s work on biomarker identification in prostate cancer is paving the way for more targeted and responsive interventions, leveraging molecular profiling to stratify patients and tailor therapies accordingly.

Another notable contribution comes from Dr. Matthew Abramowitz, who has been highlighted for his discerning role as a discussant in plenary sessions that review the latest strides in oncologic radiation research. His insights deepen the discourse around integrating emerging treatment modalities with established clinical protocols, fostering a continuous evolution in patient care standards.

Moreover, the investigation led by Dr. Alexandra Dreyfuss propels forward the realm of hematologic malignancies, specifically evaluating the synergistic effects of pembrolizumab combined with involved-site radiation therapy in Hodgkin lymphoma. Her multicenter Phase II prospective trial is emblematic of the strategic convergence between immunotherapy and focused radiation, suggesting enhanced therapeutic indices and improved disease control.

Dr. Bredel articulates that this phase of innovation is not merely incremental but transformative, representing a paradigm shift whereby radiation oncology transcends traditional boundaries. This shift is characterized by a relentless commitment to precision and individualized patient-centric care. The work at Sylvester exemplifies how technology and clinical expertise amalgamate to deliver solutions that were once considered unattainable, fundamentally altering the prognosis and quality of life for patients afflicted with complex neurological and oncological conditions.

ASTRO 2025 serves as an ideal platform for disseminating these advances to a global audience of over 11,000 professionals spanning the spectrum of radiation oncology disciplines. The annual meeting’s focus on “Rediscovering Radiation Medicine and Exploring New Indications” aptly captures the spirit of innovation permeating this year’s sessions. Alongside scientific presentations and keynote lectures, hands-on workshops and technology showcases foster a collaborative atmosphere where ideas cross-pollinate and novel hypotheses take shape.

The significance of Sylvester’s comprehensive involvement—encompassing moderatorship and varied oral and poster presentations—reflects the institution’s leadership in driving research that intersects scientific rigor and clinical application. Their work not only escalates the understanding of radiation biology and physics but also integrates translational science approaches to maximize therapeutic impact.

In many respects, the strides showcased at ASTRO 2025 exemplify how precision medicine is being actualized within radiation oncology, leveraging advances in imaging, molecular diagnostics, and immunotherapy. This multi-disciplinary synergy underscores a future where treatment regimens are increasingly tailored to an individual’s biological makeup, disease characteristics, and therapeutic responsiveness, heralding improved survival and quality of life metrics.

At the apex of these developments lies the promise of functional radiosurgery in neurological disorders. It serves as a flagship example illustrating that non-invasive, image-guided interventions can safely and effectively recalibrate dysfunctional neural circuits. Such progress not only challenges existing paradigms but inspires further inquiry into the untapped potential of radiosurgical applications across a broader range of neurological and oncologic diseases.

Sylvester Comprehensive Cancer Center’s contributions at ASTRO 2025 spotlight a wave of innovation that is reshaping the landscape of cancer and neurological treatment. From the molecular to the macroscopic level, these breakthroughs advocate for an era where precision, personalization, and patient empowerment are inextricable from the mission of contemporary radiation oncology.

As these novel methodologies gain traction and clinical validation, they hold the potential to revolutionize standard care protocols, reduce healthcare burdens, and most importantly, enhance patient outcomes. The integration of image-guided radiosurgery with emerging systemic therapies epitomizes the holistic approach needed to confront the complexities of cancer and neurological disorders in the twenty-first century.

In conclusion, the 2025 conference highlights represent not just a collection of advancements but a profound movement toward redefining therapeutic possibilities. Dr. Bredel’s leadership and the broader research efforts at Sylvester echo a transformative vision—a future where cutting-edge science and compassionate clinical care coalesce to overcome the formidable challenges of disease.

Subject of Research: Advances in Image-Guided Radiosurgery for Neurological Disorders and Emerging Radiation Oncology Techniques

Article Title: Precision Without Incision: Redefining Functional Radiosurgery and Radiation Oncology at ASTRO 2025

News Publication Date: September 30, 2025

Web References:

• https://news.med.miami.edu/precision-and-innovation-sylvester-comprehensive-cancer-center-at-astro-2025/
• https://med.miami.edu/faculty/markus-bredel-md-phd
• https://med.miami.edu/faculty/amanda-rivera-md
• https://med.miami.edu/faculty/alan-dal-pra-md
• https://med.miami.edu/faculty/matthew-c-abramowitz-md
• https://med.miami.edu/faculty/alexandra-danielle-dreyfuss

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Cancer research, Radiology, Oncology

SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation therapy (SBRT) reported fewer declines in bowel, urinary and sexual functioning but were more likely to experience a rise in prostate-specific antigen (PSA). Initial results of the NRG Oncology GU005 trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

“These findings provide important new evidence to help guide treatment decisions for patients with localized prostate cancer, a disease with typically high cure rates and long life expectancy,” said Rodney Ellis, MD, principal investigator of the trial and a professor of radiation oncology at the University of South Florida/Tampa General Hospital. “The results help clarify what patients can expect from shorter versus longer courses of radiation therapy and enable more personalized treatment decisions based on individual priorities.”

Prostate cancer is the most common solid tumor in male patients. Roughly 70,000 U.S. adults each year are diagnosed with intermediate-risk disease confined to the prostate, for which radiation therapy is a standard treatment option. Historically, patients received external beam radiation in 35 to 45 daily sessions over seven to nine weeks, but research over the past decade has established moderately hypofractionated courses of 20 to 28 sessions over four to six weeks as equally effective.

More recently, investigators have tested whether SBRT, which delivers higher doses in as few as five sessions, can further shorten the course of therapy while maintaining high cure rates. SBRT uses advanced imaging and treatment planning techniques to target tumors with extreme precision, minimizing radiation exposure to nearby organs such as the bladder and rectum. The approach offers practical advantages, including fewer visits, less travel and lower average costs, but it requires specialized technology and expertise that may not be widely available.

The NRG-GU005 trial was designed to test whether SBRT would outperform moderately hypofractionated radiation for both cancer control and patient-reported outcomes. Researchers enrolled 698 patients with previously untreated, intermediate-risk localized prostate cancer across multiple centers internationally from 2017 to 2022.

Participants were randomly assigned to receive either SBRT (36.25 Gy in five fractions, n=353) or moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT, 70 Gy in 28 fractions or 60 Gy in 20 fractions, n=345). Co-primary endpoints combined clinical measures of disease control with patient-reported outcomes collected via questionnaires administered at baseline, 12 months and 24 months after treatment to track whether patients experienced clinically meaningful declines in bowel, urinary or sexual functioning.

Fewer patients treated with SBRT reported a clinically meaningful decline in bowel function at two years (34.9% vs. 43.8% with MH-IMRT, p=0.034). Overall urinary quality of life was equivalent between the groups, but urinary incontinence was less common two years after SBRT (declines for 25.9% vs. 34.7% with MH-IMRT, p=0.023). Sexual function scores favored SBRT at one year (34% vs. 44%, respectively, p=0.026) but were similar at two years (43 vs. 41%, p=0.67).

Regarding disease-free survival, 88.6% of patients in the SBRT group were free from disease progression after three years, compared to 92.1% receiving longer courses of radiation. The difference was driven mainly by higher rates of biochemical failure, or rising PSA after treatment, in the SBRT arm (7.8% vs. 4.2%, p=0.037).

“The PSA findings require careful interpretation,” noted Dr. Ellis. “With treatments involving larger doses per fraction, patients can experience temporary PSA elevations, or ‘benign bounces,’ that resolve over time. We need five-year follow-up to determine whether these elevations translate into actual disease progression.”

The GU005 trial used a lower total SBRT dose than other recent studies (36.25 vs. 40 Gy), which Dr. Ellis said may alternatively explain the higher rate of PSA progression. By comparison, the PACE-B trial, reported at ASTRO in 2023, found equivalent cancer control with the higher dose, though with increased bowel side effects. Longer follow-up from GU005 will help clarify whether the lower dose affects long-term outcomes.

Local recurrence rates did not differ between the arms (1.2% SBRT vs. 1.0% MH-IMRT at 3 years, p=0.97), and three-year overall survival was equally high at 97% in each group (p=0.62). Severe genitourinary complications were rare with either treatment, though less common with SBRT (0.6% vs. 2.5%, p=0.04).

The study also found that rectal spacers, which are gel-like devices that temporarily separate the rectum from the radiation field, appeared to reduce bowel side effects in both treatment groups when used (in 56% of patients on the SBRT arm and 55% on the IMRT arm).

Dr. Ellis said future research will address SBRT’s potential for patients with higher-risk disease and test additional strategies to further reduce side effects while maintaining survival outcomes. For now, he said patients with intermediate-risk prostate cancer have clearer information to guide their treatment decisions: more convenient treatment with better quality of life outcomes, or longer therapy courses with potentially stronger biochemical cancer control.

“Patients have different priorities and values when it comes to their care,” Dr. Ellis noted. “Some may prioritize convenience and minimizing impact on daily life, while others focus primarily on achieving the strongest possible cancer control measures. These results help inform those deeply personal decisions.”

###

This release includes updated study results/data from the authors. Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting is requested.

Register here for a news briefing featuring this study on Tuesday, Sept. 30 at 8:00 a.m. Pacific.

Study and Presentation Details

• Abstract 1: Primary results from NRG-GU005: A phase III Trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer
• Session details and virtual meeting link
• Dr. Ellis’ bio and disclosures
• The NRG-GU005 trial (NCT03367702) was conducted by NRG Oncology with support from the National Cancer Institute and the National Institutes of Health
• More information about the meeting can be found in our press kit.

About ASTRO
The American Society for Radiation Oncology (ASTRO) is the world’s largest professional society dedicated to advancing radiation oncology, with 10,000 members including physicians, nurses, physicists, radiation therapists, dosimetrists and other professionals who work to improve patient outcomes through clinical care, research, education and policy advocacy. Radiation therapy is integral to 40% of cancer cures worldwide, and more than one million Americans receive radiation treatments for their cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and connect with us on social media.

Meeting

American Society for Radiation Oncology (ASTRO) 2025Annual Meeting

OPSCC, a malignancy originating in the middle part of the throat, has been increasing in incidence globally, largely driven by the spread of human papillomavirus (HPV). This cancer predominantly affects men but represents the second most common HPV-related cancer in women. Standard intervention for this disease stage couples IMRT with concurrent chemotherapy, proven effective in tumor control but often accompanied by debilitating side effects such as severe dysphagia. These adverse reactions can necessitate feeding tube placement, profoundly affecting patient quality of life.

IMRT is a photon-based radiation delivery technique that employs precise modulation of the intensity of beams, sculpting radiation doses conformally to tumor geometry. While highly effective in eradicating tumor cells, this approach inadvertently exposes surrounding healthy tissues to low doses of scattered radiation, sometimes precipitating unwanted toxicities. Proton beam therapy, by contrast, uses charged particles with distinct dosimetric properties, enabling high radiation deposition at the tumor site with rapid dose falloff beyond the target. This theoretically allows greater sparing of normal tissues and a potentially improved side effect profile, but it requires highly specialized equipment and remains significantly more costly and less accessible.

The TORPEdO trial enrolled 205 patients with locally advanced OPSCC between 2020 and 2023, assigning them in a 2:1 ratio to receive either intensity-modulated proton therapy (IMPT) or IMRT, both administered alongside cisplatin chemotherapy. Demographically, the study population skewed predominantly male, with a median age of approximately 57 years and relatively low tobacco exposure, reflecting typical contemporary HPV-driven OPSCC patient profiles. The rigorously designed trial integrated both clinical and patient-reported outcomes as co-primary endpoints, focusing on feeding tube dependency, critical weight loss, and subjective assessments of side effects and quality of life via validated questionnaires.

After one year post-treatment, results strikingly demonstrated comparable and remarkably low feeding tube dependence in both treatment arms, with only 1.7% of patients in each group requiring ongoing nutritional support via gastrostomy. Interestingly, severe weight loss was more frequently observed in the proton therapy cohort (18.2%) as opposed to the IMRT arm (5.7%), though the aggregate composite clinical endpoint encompassing weight loss and feeding tube usage did not reveal statistically significant differences (p=0.08). These clinical findings run counter to expectations generated by prior preliminary research and prevailing hypotheses favoring proton therapy’s physical advantages.

Complementing clinical metrics were patient-reported outcome measures, which constitute a critical dimension in assessing cancer treatment’s holistic impact. No significant differences emerged on composite functional scales including saliva production, taste, chewing, swallowing, speech, and appearance, with scores nearly identical between the two modalities. Similarly, swallowing function assessments using the MD Anderson Dysphagia Inventory revealed virtually overlapping results, dispelling assumptions that proton therapy’s superior physical dose distribution translates straightforwardly into enhanced patient-perceived functional outcomes.

The TORPEdO trial’s rigorous quality assurance protocols fortified the validity of these findings, ensuring high fidelity in treatment planning and delivery across both arms. Conducted under the strict oversight of the UK’s National Radiotherapy Trials Quality Assurance Group, the trial guarantees that each patient received state-of-the-art care adhering to exacting standards, thereby isolating the modality choice as the variable of interest. This methodological robustness bolsters confidence in concluding that high-quality IMRT remains an excellent therapeutic standard for advanced OPSCC.

Furthermore, long-term oncologic outcomes echoed this trend of equivalence. With a median follow-up exceeding two years, both treatment arms exhibited outstanding local control rates nearing 95% and similar overall survival metrics, affirming that neither modality compromises efficacy. Proton therapy’s capacity to reduce radiation dose to adjacent critical structures, while demonstrable dosimetrically, did not translate into measurable differences in chronic toxicity or quality-of-life enhancements within this population and timeframe.

This body of evidence aligns with and adds nuance to previous studies that suggested proton therapy could reduce feeding tube dependency during the immediate post-treatment period, highlighting the importance of longitudinal assessment of patient outcomes. The absence of significant late outcome disparities suggests that reductions in radiation dose alone, though necessary, may not be sufficient criteria for widespread adoption of proton therapy in this clinical context, especially given its resource-intensive nature.

In sum, the TORPEdO trial represents a landmark inquiry providing robust, high-level evidence that modern, meticulously delivered IMRT achieves excellent disease control and maintains patient quality of life on par with proton therapy for locally advanced OPSCC. These insights advocate for the continued utilization of IMRT, a more accessible and cost-effective modality, while underscoring the imperative to explore novel strategies that could further minimize toxicity and enhance survivorship beyond radiation delivery technique alone.

The implications of TORPEdO resonate broadly within the radiation oncology community, informing clinical practice, health economics, and patient counseling. As proton therapy facilities remain limited and expensive globally, these findings will influence policy and reimbursement discussions, reinforcing the principle that advanced technology must demonstrably improve meaningful patient outcomes to justify widespread implementation. Future research directions may include investigational combinations of radiation with emerging systemic therapies, personalized adaptive treatment approaches, and integration of biomarkers predicting toxicity risk.

Significantly, TORPEdO’s focus on patient-reported outcomes as co-primary endpoints epitomizes the evolution of cancer trials towards embedding patient perspectives at the heart of clinical decision-making. By demonstrating that therapy choices leading to equivalent survival also yield comparable patient experiences, the trial empowers patients and clinicians to make informed decisions balancing efficacy, quality of life, logistical considerations, and healthcare resources. This paradigm shift heralds a new era in head and neck cancer management, where technological innovation must be married with rigorous evidence and patient-centered care.

The advanced dosimetry of proton therapy delivers lower radiation doses to adjacent swallowing muscles and salivary glands, a theoretically advantageous profile. However, the lack of corresponding functional improvement after one year highlights the complex, multifactorial nature of radiation-induced toxicity, which likely involves biological and rehabilitative factors beyond radiation dose metrics alone. This insight stimulates a reevaluation of how dosimetric data are interpreted and leveraged in clinical practice and trial design for head and neck oncology.

Dr. David Thomson, principal investigator of the TORPEdO trial and consultant clinical oncologist at The Christie NHS Foundation Trust, emphasized that while proton therapy continues to hold promise, high-caliber IMRT remains not only an effective but also a highly patient-friendly treatment modality. This highlights the critical importance of delivering advanced radiation therapy within quality-controlled frameworks, ensuring optimal outcomes regardless of technology used. Ultimately, patient-centered outcomes and accessible state-of-the-art care remain the cornerstones of progress against OPSCC.

Collectively, the TORPEdO findings represent a milestone, reframing expectations and guiding future radiation oncology strategies. They affirm that technological sophistication must be measured against tangible benefits in real-world, long-term patient experiences. These results will resonate globally, informing standards of care for thousands of patients navigating the challenges of oropharyngeal cancer treatment each year.

Subject of Research:
Oropharyngeal squamous cell carcinoma treatment using advanced radiation therapy modalities

Article Title:
TORPEdO Trial Reveals Comparable Long-Term Outcomes for Proton Therapy and IMRT in Advanced Oropharyngeal Cancer

News Publication Date:
September 29, 2025

Web References:

• American Society for Radiation Oncology (ASTRO) Annual Meeting: http://www.astro.org/annualmeeting
• TORPEdO trial abstract and session details: https://amportal.astro.org/sessions/pl-01-21644/primary-results-for-the-phase-iii-trial-of-toxicity-reduction-using-proton-beam-therapy-for-o-109477
• Related phase III study on proton therapy and IMRT comparison: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.6006

References:
TORPEdO trial data and presentation, David Thomson, MD, The Christie NHS Foundation Trust, ASTRO 2025 Annual Meeting

Keywords:
Oropharyngeal cancer, intensity-modulated radiation therapy, proton beam therapy, head and neck cancer, clinical trial, radiation toxicity, patient-reported outcomes, cancer survivorship, radiation oncology, HPV-related cancer

A groundbreaking pilot study emanating from researchers at the Fox Chase Cancer Center, recently unveiled at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, introduces a transformative approach that may redefine radiotherapy paradigms for recurrent retroperitoneal sarcomas and potentially other challenging malignancies. This innovative methodology employs CT adaptive stereotactic body radiation therapy (CTA-SBRT), harnessing advanced imaging and real-time treatment adaptation to safely administer repeat courses of radiation without compromising patient safety or quality of life.

The study, spearheaded by fifth-year radiation oncology resident Dr. Maryanne J. Lubas and overseen by Dr. Rebecca Shulman, Assistant Professor of Radiation Oncology at Fox Chase, meticulously analyzed clinical outcomes from five patients treated with this adaptive re-irradiation technique between April 2024 and January 2025. Crucially, the treatment protocol involved the creation of dual radiation plans each session: a conventional plan formulated prior to therapy and a second, dynamically optimized adaptive plan generated based on same-day cone-beam CT imaging. Across all treatment sessions, the adaptive plan consistently demonstrated superior dosimetric performance, enabling enhanced precision targeting of tumorous tissue while minimizing exposure to surrounding healthy structures.

This adaptive process leverages the Ethos cone-beam CT system integrated with sophisticated artificial intelligence algorithms capable of recalibrating radiation dose distribution in real time. By allowing on-the-fly adjustments to the treatment plan while the patient remains immobilized on the treatment couch, clinicians can rapidly respond to minute anatomical changes, such as tumor regression, patient weight fluctuations, or internal organ motion. The result is a significant improvement in therapeutic ratio—amplifying tumoricidal doses by an average of 7.7% while concomitantly reducing the radiation burden on critical organs such as the small intestine by approximately 21%.

Perhaps most strikingly, this pioneering application of CTA-SBRT achieved excellent safety profiles. Patients tolerated the adaptive re-irradiation without any serious adverse events or the need for emergency surgical interventions, thereby preserving essential physiological functions including bowel and bladder control. This outcome underscores a paradigm shift from merely providing palliative benefit towards achieving durable control of these notoriously recalcitrant tumors, which was hitherto almost unattainable with conventional radiation strategies.

The successful integration of adaptive radiation therapy reflects a convergence of cutting-edge imaging, computational power, and clinical expertise. Traditional radiation oncology paradigms have long been hampered by rigid treatment plans developed prior to therapy initiation, which do not accommodate the dynamic biological and spatial changes occurring during a multiday treatment course. Adaptive therapy surmounts this limitation by iterative plan optimization at each visit, ensuring that radiation delivery conforms to the current tumor morphology and anatomical context with remarkable fidelity.

Fox Chase Cancer Center’s commitment to advancing adaptive radiotherapy extends well beyond retroperitoneal sarcomas. As pioneers in this discipline, they were the first institution nationally to initiate a prostate cancer clinical trial deploying this technology. Over the past year, their cohort has broadened considerably, now encompassing complex cancers of the bladder, liver, pancreas, breast, lung, and head and neck. This expansive implementation attests to the adaptability and broad applicability of the Ethos platform and AI-driven treatment planning in diverse oncologic scenarios.

Achieving this level of adaptive precision required immense institutional investment in infrastructure, cross-disciplinary training, and collaborative workflows. Every radiation oncologist at Fox Chase is extensively trained to offer adaptive therapy as a frontline option for eligible patients, working seamlessly with a dedicated cadre of PhD medical physicists who execute real-time plan recalibrations alongside clinicians within the linear accelerator treatment suite. This tightly integrated model exemplifies how multidisciplinary synergy can catalyze technological innovation into tangible patient benefits.

The implications of this technology extend far beyond technical refinement; they herald an era in which radiation therapy is truly personalized and dynamically tailored, shifting the therapeutic paradigm from a one-size-fits-all model to a continuously evolving, patient-specific intervention. This approach not only enhances the efficacy of oncologic control but also significantly mitigates toxicities that historically limited repeat treatments, thereby expanding options for patients previously considered untreatable.

Looking forward, the Fox Chase team plans to longitudinally monitor patients enrolled in the retroperitoneal sarcoma pilot study while simultaneously expanding clinical trials to validate adaptive radiation therapy across a wider spectrum of malignancies. Their pioneering work lays a foundation for reimagining cancer treatment as a responsive, adaptive process — an innovation that could dramatically improve outcomes and quality of life for countless patients confronting the daunting challenge of recurrent or resistant tumors.

As radiation oncology continues to evolve at the nexus of technology, biology, and clinical medicine, adaptive radiotherapy epitomizes the future: a marriage of precision imaging, artificial intelligence, and expert human oversight that redefines what is possible in cancer care. This breakthrough study is not merely an incremental step but a leap forward, suggesting that where standard treatment once reached its limits, new adaptive modalities can forge paths toward hope, control, and potentially even cure in some of the most challenging oncologic landscapes.

Subject of Research: People
Article Title: (Not provided)
News Publication Date: 28-Sep-2025
Web References: Fox Chase Cancer Center, ASTRO 2025 Annual Meeting
References: (Not provided)
Image Credits: (Not provided)
Keywords: Sarcoma, Cancer

The 2025 ASTRO Annual Meeting, recognized as the premier scientific forum dedicated to radiation oncology, will spotlight a diverse array of clinical trials and studies emphasizing next-generation technologies. Investigations into radiopharmaceutical therapies and novel uses of low-dose radiation therapy are of particular interest. These studies stand at the intersection of precision medicine and radiation science, illustrating a trend toward tailored therapeutic regimens that maximize efficacy while minimizing patient morbidity. Researchers will present early results from cutting-edge trials targeting prostate, breast, lung, and other prevalent cancer types, elucidating the ways radiation modalities are evolving in response to molecular and clinical challenges.

Central to the meeting’s agenda are several randomized controlled trials that promise to refine therapeutic strategies in oncology. For instance, the NRG GU006 BALANCE trial explores the synergistic potential of combining apalutamide, an androgen receptor inhibitor, with radiotherapy in recurrent prostate cancer patients. This double-blind, placebo-controlled, biomarker-stratified study aims to deepen understanding of how hormonal manipulation can potentiate radiation effects, offering a path toward improved biochemical control and potentially delaying disease progression in this patient population.

Another key investigation focuses on the use of low-dose radiation therapy (LDRT) in non-malignant conditions, notably knee osteoarthritis. A randomized, sham-controlled trial assessing the short-term clinical effectiveness of a single course of LDRT has been conducted, highlighting radiation’s anti-inflammatory and analgesic properties. These findings could significantly impact treatment paradigms for musculoskeletal disorders, potentially offering a non-invasive alternative to conventional pharmacotherapy or surgery, especially for patients contraindicated for systemic medications.

Bladder cancer management is also receiving renewed attention with the Bladder Adjuvant RadioTherapy (BART) trial, which reports clinical outcomes from a phase III multicenter randomized controlled trial. This study evaluates radiation as an adjuvant modality post-surgery, aiming to reduce local recurrence and improve overall survival rates. The nuanced assessment of therapeutic benefit versus toxicity risks in this setting is critical given the bladder’s sensitivity and the need to preserve urinary function.

Combining molecular radioisotopes with targeted radiotherapy represents another frontier, exemplified by the phase II LUNAR trial. This study investigates ^177Lutetium-PSMA, a radiolabeled molecule targeting prostate-specific membrane antigen, administered as neoadjuvant therapy before ablative radiotherapy in oligorecurrent prostate cancer. The primary endpoint analysis of this trial may provide valuable insights into how molecular targeting can enhance radiation delivery to microscopic disease, potentially improving local control while sparing normal tissues.

In parallel, cardiac applications of stereotactic arrhythmia radiotherapy (STAR) are emerging as a groundbreaking non-invasive alternative to catheter ablation for refractory ventricular tachycardia. The 3-year safety and efficacy outcomes from this comparative study suggest that STAR may offer durable arrhythmia suppression with a favorable risk profile, introducing radiation therapy into the realm of cardiac electrophysiology and expanding its clinical utility beyond oncology.

On September 30, the focus will shift to comparative effectiveness trials examining proton versus photon therapy in breast and head and neck cancers. The RADCOMP consortium’s phase III trial assesses health-related quality of life outcomes in patients receiving comprehensive nodal radiation for non-metastatic breast cancer. By leveraging proton therapy’s superior dose distribution and sparing of adjacent healthy tissues, this study aims to validate whether this modality translates into meaningful clinical benefits, including reduced toxicity and enhanced patient-reported outcomes.

Complementing this, the TORPEdO trial reports on toxicity reduction achieved through proton beam therapy for oropharyngeal cancer, another indication where precise targeting can mitigate the debilitating side effects traditionally associated with photon-based radiation. These studies together underscore the ongoing shift towards personalized radiotherapy, where treatment choice is increasingly guided by the balance of tumor control and normal tissue preservation.

Further redefining hypofractionated radiation strategies, the NRG-GU005 trial compares stereotactic body radiotherapy (SBRT) with hypofractionated intensity-modulated radiation therapy (IMRT) in localized intermediate-risk prostate cancer. This phase III trial meticulously evaluates oncologic outcomes alongside patient quality of life, potentially setting the stage for more convenient and equally effective treatment regimens that maintain tumor control with fewer sessions and reduced toxicity.

In lung cancer, long-term data from the revised STARS trial offers a decade of follow-up comparing radiation therapy with surgical intervention in early-stage non-small cell lung cancer. These data provide invaluable guidance on patient selection criteria and reinforce radiation as a modality capable of delivering comparable survival outcomes with reduced procedural risk, particularly important for medically inoperable patients.

The overarching theme of this year’s meeting, “Rediscovering Radiation Medicine and Exploring New Indications,” captures a transformative moment where radiation therapy is expanding into territories previously underexplored. Beyond malignancy, radiation’s role in treating musculoskeletal conditions such as plantar fasciitis and osteoarthritis, cardiac disorders including arrhythmias and early heart failure, and functional neurologic diseases like Parkinsonian tremors is gaining momentum. These novel indications highlight radiation’s capacity to modulate biological pathways involved in inflammation, fibrosis, and neural dysfunction.

This multidisciplinary approach is championed by ASTRO President Sameer Keole, MD, whose Presidential Symposium will delve into these emerging clinical arenas. His vision aligns with technological advancements and enhanced biological understanding that potentiate the safe application of radiotherapy in diverse disease states, potentially revolutionizing standard care and expanding therapeutic possibilities.

The meeting expects to convene over 10,000 oncologists, clinicians, and researchers worldwide. With more than 2,500 abstract presentations and educational panels, alongside keynote addresses from leaders like American Medical Association President Bobby Mukkamala, MD, who bravely shares his personal journey with a brain tumor, and Stanford professor Bryant Lin, MD, MEng, living with stage 4 lung cancer, ASTRO’s 2025 Annual Meeting represents a nexus of innovation, patient advocacy, and scientific rigor.

For media representatives, detailed briefing sessions on September 29 and 30 will present these high-impact studies, offering an unparalleled opportunity to gain in-depth perspectives from principal investigators and clinical experts. The convergence of technological innovation, clinical trials, and multidisciplinary collaboration positions radiation oncology at the cutting edge of medical science, with profound implications for cancer treatment and beyond.

Visitors and participants can access comprehensive schedules and presenter information via ASTRO’s Annual Meeting portal, ensuring seamless engagement with this landmark event. As radiation oncology continues to evolve, ASTRO remains the globally recognized leader driving research, education, and policy advocacy to improve cancer patient outcomes and expand the horizons of radiation medicine.

Subject of Research: Advances in radiation oncology including radiopharmaceutical therapy, low-dose radiation applications, and novel trials in cancer and non-cancer indications.

Article Title: ASTRO 2025 Annual Meeting Unveils Next-Generation Advances in Radiation Medicine

News Publication Date: September 4, 2025

Web References:

• https://www.astro.org/annualmeetingpress
• http://www.astro.org/annualmeeting
• http://www.rtanswers.org

Keywords: Cancer, Prostate cancer, Metastasis, Breast cancer, Lung cancer, Head and neck cancer, Oncology, Cancer patients, Personalized medicine

Radiation therapy has historically been a cornerstone in oncologic care, contributing to approximately 40% of global cancer cures and serving millions annually, particularly within the United States. However, the 2025 ASTRO meeting will prominently feature emerging evidence on the use of radiation as a therapeutic modality beyond oncology, delving into its potential efficacy in managing musculoskeletal conditions like osteoarthritis, certain cardiac arrhythmias, and neurological dysfunctions such as Parkinsonian tremors. This signifies a paradigm shift, broadening the clinical indications and integrating radiation medicine into diverse therapeutic algorithms.

Central to the conference will be the dissemination of over 2,500 peer-reviewed research presentations and posters. These contributions encompass cutting-edge advancements in radiation delivery techniques, radiobiological insights, novel radiopharmaceutical therapy protocols, and innovations in treatment planning that enhance precision and minimize collateral tissue damage. Attendees will engage with rigorous scientific content that elucidates molecular mechanisms of radiation response and resistance, fostering an environment where translational applications can swiftly move from bench to bedside.

The scientific sessions will not only emphasize technical proficiency but will also address crucial aspects of patient survivorship, particularly focusing on adolescents and young adults who have undergone cancer treatment. This demographic presents unique challenges related to long-term treatment sequelae and quality-of-life outcomes, making survivorship an essential area for multidisciplinary research and clinical pathway development. Additionally, special attention will be directed toward cancer care delivery in conflict zones and resource-limited settings, highlighting the intersection of oncology, global health, and humanitarian medicine.

Keynote presentations promise to provide a compelling human dimension to the conference. Notably, Dr. Bobby Mukkamala, president-elect of the American Medical Association who experienced a grade 2 brain tumor resection in late 2024, will share his insights, bridging clinical decision-making with the lived patient experience. Furthermore, Dr. Bryant Lin, a Stanford Medicine professor living with stage 4 lung cancer, will offer a nuanced perspective on therapy outcomes and patient resilience, enriching the scientific discourse with empathy and real-world relevance.

A highlight of the meeting comprises the Presidential Symposium, dedicated to synthesizing existing and emergent data concerning radiation’s role in treating non-cancer conditions. This session will convene a multidisciplinary panel of experts spanning oncology, cardiology, neurology, and rehabilitation medicine. Discussions will delve into radiobiological mechanisms underpinning therapeutic efficacy in non-malignant tissues, dose fractionation strategies tailored to chronic inflammatory states, and safety profiles crucial for expanding radiation’s clinical applications.

The ASTRO 2025 Annual Meeting will facilitate hybrid participation through both in-person attendance in San Francisco and virtual livestreams, ensuring broad accessibility. This dual format enhances collaborative opportunities and knowledge dissemination, catering to a global audience. On-site attendees will also have the opportunity to explore the latest innovations in patient care technologies within the Exhibit Hall, where vendors and research institutions will showcase breakthroughs in imaging, treatment delivery systems, and software platforms for radiation oncology.

Parallel to the scientific program, ASTRO will host a series of news briefings spotlighting high-impact research findings. Details of these briefings will be announced closer to the meeting date, providing accredited press with in-depth access to groundbreaking studies. The presence of a dedicated press office and interview facilities at the Moscone Center underscores ASTRO’s commitment to transparent and effective communication between researchers and the public.

As radiation oncology continues to evolve, ASTRO’s role as the largest global radiation oncology society—counting over 10,000 multidisciplinary members—remains critical. This annual meeting represents not only a convergence of scientific excellence but also a forum for advancing the integration of radiation therapy into a broader spectrum of clinical practice. Innovations discussed at this event will shape future standards of care, improve therapeutic precision, and potentially transform patient outcomes across oncologic and non-oncologic diseases.

Participants and interested parties are encouraged to register early through ASTRO’s official meeting portals, whether as media or general attendees. This proactive engagement ensures access to the comprehensive educational offerings and networking opportunities integral to professional growth and the advancement of radiation medicine.

In sum, the 67th ASTRO Annual Meeting epitomizes a transformative moment for radiation oncology. By blending rigorous scientific investigation, patient-centered narratives, and multidimensional clinical perspectives, it heralds a new era where radiation therapy’s utility extends beyond cancer, catalyzing innovations that promise enhanced patient care worldwide.

Subject of Research: Radiation therapy advancements and expanding clinical applications beyond oncology
Article Title: ASTRO 2025 Annual Meeting: Exploring New Frontiers in Radiation Medicine
News Publication Date: May 15, 2025
Web References:

• https://www.astro.org/annualmeeting
• https://www.astro.org/annualmeetingpress
• http://www.rtanswers.org/
  Keywords: Radiation therapy, Cancer treatments, Oncology, Cancer research, Clinical trials, Scientific conferences, Cancer patients